← Back to Clinical Trials
Recruiting Phase 1 NCT05218850

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Ulcerative Colitis
Sponsor Children's Hospital Los Angeles
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 10
Sex ALL
Min Age 7 Years
Max Age 21 Years
Start Date 2022-06-29
Completion 2027-06-30
Interventions
Butyrate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.

Eligibility Criteria

Inclusion Criteria: * 7-21 years, mild to moderate ulcerative colitis Exclusion Criteria: * UC therapy within 4 weeks of study medication initiation * infectious colitis, -pregnancy

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE ULCERATIVE COLITIS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}